\contentsline {section}{\numberline {1}Introduction}{4}{section.1}
\contentsline {section}{\numberline {2}Results}{5}{section.2}
\contentsline {subsection}{\numberline {2.1}The \texttt {extTADA} pipeline}{5}{subsection.2.1}
\contentsline {subsection}{\numberline {2.2}Test \texttt {extTADA} on simulated data. }{7}{subsection.2.2}
\contentsline {subsubsection}{\numberline {2.2.1}Test \texttt {extTADA} for only CC data}{7}{subsubsection.2.2.1}
\contentsline {subsubsection}{\numberline {2.2.2}Evaluate the performance on integrated DN and CC data}{9}{subsubsection.2.2.2}
\contentsline {subsection}{\numberline {2.3}Schizophrenia data sets}{10}{subsection.2.3}
\contentsline {subsubsection}{\numberline {2.3.1}Extract data sets to analyze integratively}{10}{subsubsection.2.3.1}
\contentsline {subsubsection}{\numberline {2.3.2}Integrated analysis of de novo mutations and case-control variants}{11}{subsubsection.2.3.2}
\contentsline {subsubsection}{\numberline {2.3.3}Test enrichment of SCZ-risk genes in gene sets}{14}{subsubsection.2.3.3}
\contentsline {paragraph}{\numberline {2.3.3.1}Top SCZ significant genes from \texttt {extTADA} are enriched in known gene sets}{14}{paragraph.2.3.3.1}
\contentsline {paragraph}{\numberline {2.3.3.2}Top SCZ genes are enriched in other gene sets from a data-driven approach}{15}{paragraph.2.3.3.2}
\contentsline {subsubsection}{\numberline {2.3.4}Identify number of risk genes for SCZ studies with different sample sizes}{17}{subsubsection.2.3.4}
\contentsline {subsubsection}{\numberline {2.3.5}Test for single classes of SCZ data}{17}{subsubsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.6}Test genetic architecture of SCZ using both InExAC and NoExAC variants}{18}{subsubsection.2.3.6}
\contentsline {subsubsection}{\numberline {2.3.7}Test the influence of mutation rates to the analyzing results of SCZ}{18}{subsubsection.2.3.7}
\contentsline {subsection}{\numberline {2.4}Estimate genetic parameters of other neurodevelopmental diseases using extTADA}{18}{subsection.2.4}
\contentsline {subsection}{\numberline {2.5}Novel risk genes in ID and DD diseases.}{20}{subsection.2.5}
\contentsline {section}{\numberline {3}Discussion}{21}{section.3}
\contentsline {section}{\numberline {4}Data and methods}{23}{section.4}
\contentsline {subsection}{\numberline {4.1}Data}{24}{subsection.4.1}
\contentsline {subsubsection}{\numberline {4.1.1}Simulation data}{24}{subsubsection.4.1.1}
\contentsline {subsubsection}{\numberline {4.1.2}Variant data of SCZ, ID, DD, EPI and ASD}{24}{subsubsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.3}Gene sets}{24}{subsubsection.4.1.3}
\contentsline {paragraph}{\numberline {4.1.3.1}Known gene sets}{25}{paragraph.4.1.3.1}
\contentsline {paragraph}{\numberline {4.1.3.2}Other gene sets}{26}{paragraph.4.1.3.2}
\contentsline {subsection}{\numberline {4.2}Methods}{26}{subsection.4.2}
\contentsline {subsubsection}{\numberline {4.2.1}\texttt {extTADA} pipeline: analyze de novo, transmission and case-control data}{26}{subsubsection.4.2.1}
\contentsline {paragraph}{\numberline {4.2.1.1}\texttt {extTADA} for one de novo population and one case/control population}{26}{paragraph.4.2.1.1}
\contentsline {paragraph}{\numberline {4.2.1.2}Simplified approximate case/control model}{27}{paragraph.4.2.1.2}
\contentsline {paragraph}{\numberline {4.2.1.3}Control of the proportion of protective vs risk variants using the mean and dispersion parameters of relative risks}{27}{paragraph.4.2.1.3}
\contentsline {paragraph}{\numberline {4.2.1.4}\texttt {extTADA} for multiple populations}{27}{paragraph.4.2.1.4}
\contentsline {paragraph}{\numberline {4.2.1.5}Predict the number of risk genes}{28}{paragraph.4.2.1.5}
\contentsline {subsubsection}{\numberline {4.2.2}Use simulation data to test model}{28}{subsubsection.4.2.2}
\contentsline {subsubsection}{\numberline {4.2.3}Calculate mutation rates}{29}{subsubsection.4.2.3}
\contentsline {subsubsection}{\numberline {4.2.4}Analyze SCZ data}{29}{subsubsection.4.2.4}
\contentsline {paragraph}{\numberline {4.2.4.1}Obtain non-heterogeneous populations for case-control data of SCZ}{29}{paragraph.4.2.4.1}
\contentsline {paragraph}{\numberline {4.2.4.2}Estimate genetic parameters for SCZ}{30}{paragraph.4.2.4.2}
\contentsline {paragraph}{\numberline {4.2.4.3}Estimate number of risk genes for SCZ}{30}{paragraph.4.2.4.3}
\contentsline {paragraph}{\numberline {4.2.4.4}Test enrichment in known gene sets}{30}{paragraph.4.2.4.4}
\contentsline {paragraph}{\numberline {4.2.4.5}Predict number of risk genes for different sample sizes}{31}{paragraph.4.2.4.5}
\contentsline {paragraph}{\numberline {4.2.4.6}Test for single classes}{31}{paragraph.4.2.4.6}
\contentsline {paragraph}{\numberline {4.2.4.7}Test genetic architecture of SCZ using both InExAC and NoExAC variants}{31}{paragraph.4.2.4.7}
\contentsline {paragraph}{\numberline {4.2.4.8}Test the influence of mutation rates to the analyzing results of SCZ}{31}{paragraph.4.2.4.8}
\contentsline {subsubsection}{\numberline {4.2.5}Use \texttt {extTADA} to predict genetic parameters of other neurodevelopmental diseases}{31}{subsubsection.4.2.5}
\contentsline {subsubsection}{\numberline {4.2.6}Infer parameters using MCMC results}{31}{subsubsection.4.2.6}
\contentsline {section}{\numberline {5}Acknowledgements}{32}{section.5}
\contentsline {section}{\numberline {6}Supplementary information}{33}{section.6}
\contentsline {subsection}{\numberline {6.1}Sup Table}{33}{subsection.6.1}
\contentsline {subsection}{\numberline {6.2}Sup Figure}{41}{subsection.6.2}
\contentsline {subsection}{\numberline {6.3}Sup Information}{47}{subsection.6.3}
\contentsline {paragraph}{\numberline {6.3.0.1}Calculate Bayes Factor for case/control data}{47}{paragraph.6.3.0.1}
